Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants.

导出 OA

翻译打印收藏纠错

作者： Hyun,Ryu ^[1] ; Hyojin,Kim ^[1] ; Inwon,Park ^[1] ; Minki,Lee ^[1] ; Yoon Sun,Park ^[1] ; Dong-Hoon,Jin ^[2] ; Sun-Chul,Hur ^[1] ; Junho,Park ^[1] ; Hyunho,Lee ^[1]

作者单位： Wellmarkerbio Co., Ltd., Seoul 05855, Republic of Korea. ^[1] Wellmarkerbio Co., Ltd., Seoul 05855, Republic of Korea.;Department of Convergence Medicine, Asan Institute for Life Science, Asan Medical Center, Seoul 05505, Republic of Korea.;Department of Pharmacology, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. ^[2]

DOI 10.1021/acsmedchemlett.3c00206

PMID 37736180

发布时间 2024-09-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

ACS medicinal chemistry letters

2023年14卷9期

1198-1207页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants.

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants.

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

检索历史清除